NPPA fixes retail prices of 14 formulations under DPCO, 2013

  • Posted on: 3 March 2018
  • By: Shalini.Sharma

Pharma Admission

igmpi

pharma admission

igmpi

 

As per notification dated 23 February 2018, NPPA has fixed retail prices of 14 formulations under Drugs Prices Control Order, 2013.

The name of the formulations are amlodipine +, valsartan tablet (Valembic 80 AM), Amlodipine +valsartan tablet (Valembic 160 AM), paclitaxel (protein bound particles) for injectable suspension (Nabtoxol), Telmisartan +chlorthalidone tablet, glimepiride +metformin + voglibose tablet (Trivogo 2/0.3 mg), etoricoxib + paracetamol tablet, sofosbuvir + velpatasvir tablets, atorvastatin + clopidogrel capsule, rosuvastatin +aspirin + clopidogrel capsule, ferrous ascorbate + folic acid suspension, bortezomib injection and Teneligliptin + metformin HCl tablet.  

The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price.
 The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

The manufacturers not complying with the ceiling price and notes specified shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. 

Consequent to the issue of ceiling prices of such formulations as specified, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email


Latest News